Emergent BioSolutions Inc. products

VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The Reactive Skin Decontamination Lotion Kit is intended to remove or neutralize chemical warfare agents and T-2 Toxin from the skin.

ACAM2000, (Smallpox (Vaccinia) Vaccine, Live) is a live, vaccinia virus smallpox vaccine licensed in the U.S. by the Food and Drug Administration for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. It was developed under a contract with the U.S. Centers for Disease Control and Prevention (CDC).

Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. Raxibacumab is also indicated for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.